[HTML][HTML] Integrative analysis of PRKAG2 cardiomyopathy iPS and microtissue models identifies AMPK as a regulator of metabolism, survival, and fibrosis

JT Hinson, A Chopra, A Lowe, CC Sheng, RM Gupta…�- Cell reports, 2016 - cell.com
JT Hinson, A Chopra, A Lowe, CC Sheng, RM Gupta, R Kuppusamy, J O'Sullivan, G Rowe
Cell reports, 2016cell.com
AMP-activated protein kinase (AMPK) is a metabolic enzyme that can be activated by
nutrient stress or genetic mutations. Missense mutations in the regulatory subunit, PRKAG2,
activate AMPK and cause left ventricular hypertrophy, glycogen accumulation, and
ventricular pre-excitation. Using human iPS cell models combined with three-dimensional
cardiac microtissues, we show that activating PRKAG2 mutations increase microtissue twitch
force by enhancing myocyte survival. Integrating RNA sequencing with metabolomics�…
Summary
AMP-activated protein kinase (AMPK) is a metabolic enzyme that can be activated by nutrient stress or genetic mutations. Missense mutations in the regulatory subunit, PRKAG2, activate AMPK and cause left ventricular hypertrophy, glycogen accumulation, and ventricular pre-excitation. Using human iPS cell models combined with three-dimensional cardiac microtissues, we show that activating PRKAG2 mutations increase microtissue twitch force by�enhancing myocyte survival. Integrating RNA sequencing with metabolomics, PRKAG2 mutations that activate AMPK remodeled global metabolism by regulating RNA transcripts to favor glycogen storage and oxidative metabolism instead of glycolysis. As in patients with PRKAG2 cardiomyopathy, iPS cell and mouse models are protected from cardiac fibrosis, and we define a�crosstalk between AMPK and post-transcriptional regulation of TGFβ isoform signaling that has implications in fibrotic forms of cardiomyopathy. Our results establish critical connections among metabolic sensing, myocyte survival, and TGFβ signaling.
cell.com